Outcome of high-risk stage IC, grade 3, compared with stage I endometrial carcinoma patients: the Postoperative Radiation Therapy in Endometrial Carcinoma Trial.

PURPOSE Stage IC, grade 3 endometrial cancer is regarded as a high-risk category. Stage IC, grade 3 patients were not eligible for the randomized Postoperative Radiation Therapy in Endometrial Carcinoma (PORTEC) trial, but were registered and received postoperative radiotherapy. PATIENTS AND METHODS The PORTEC trial included 715 patients with stage IC, grade 1 or 2, and stage IB, grade 2 or 3 endometrial cancer. Patients were randomly assigned after surgery to receive pelvic radiotherapy (RT) or no further treatment. A total of 104 patients with stage IC, grade 3 endometrial cancer were registered, of whom 99 could be evaluated. Patterns of relapse and survival were compared with PORTEC patients receiving RT. Median follow-up was 83 months. RESULTS The actuarial 5-year rates of locoregional relapse were 1% to 3% for PORTEC patients who received RT, compared with 14% for stage IC, grade 3 patients. Five-year distant metastases rates were 3% to 8% for grade 1 and 2 tumors; 20% for stage IB, grade 3 tumors; and 31% for stage IC, grade 3 tumors. Overall survival rates were 83% to 85% for grades 1 and 2; 74% for stage IB, grade 3; and 58% for stage IC, grade 3 patients (P <.001). In multivariate analysis grade 3 was the most important adverse prognostic factor for relapse and death as a result of endometrial cancer (hazard ratios, 5.4 and 5.5; P <.0001). CONCLUSION Patients with stage IC, grade 3 endometrial carcinoma are at high risk of early distant spread and endometrial carcinoma-related death. Novel strategies for adjuvant therapy should be explored to improve survival for this patient group.

[1]  J. Thigpen,et al.  Whole abdominal radiotherapy versus combination doxorubicin-cisplatin chemotherapy in advanced endometrial carcinoma: A randomized phase III trial of the Gynecologic Oncology Group , 2003 .

[2]  Keith D. Jones,et al.  High-risk surgical stage 1 endometrial cancer: outcomes with vault brachytherapy alone. , 2003, Gynecologic oncology.

[3]  P. Roland,et al.  Stage IC adenocarcinoma of the endometrium: survival comparisons of surgically staged patients with and without adjuvant radiation therapy. , 2003, Gynecologic oncology.

[4]  M. Piccart,et al.  Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  T. Kasamatsu,et al.  Prognostic significance of positive peritoneal cytology in endometrial carcinoma confined to the uterus , 2003, British Journal of Cancer.

[6]  D. Mutch,et al.  Should the presence of lymphvascular space involvement be used to assign patients to adjuvant therapy following hysterectomy for unstaged endometrial cancer , 2002 .

[7]  Brady J. McKee,et al.  Is there a difference in outcome between stage I-II endometrial cancer of papillary serous/clear cell and endometrioid FIGO Grade 3 cancer? , 2002, International journal of radiation oncology, biology, physics.

[8]  P. Koper,et al.  The morbidity of treatment for patients with Stage I endometrial cancer: results from a randomized trial. , 2001, International journal of radiation oncology, biology, physics.

[9]  A. Mundt,et al.  Significant pelvic recurrence in high-risk pathologic stage I--IV endometrial carcinoma patients after adjuvant chemotherapy alone: implications for adjuvant radiation therapy. , 2001, International journal of radiation oncology, biology, physics.

[10]  K. Stelzer,et al.  Radiation therapy in endometrial cancer. , 2001, Best practice & research. Clinical obstetrics & gynaecology.

[11]  B. Jereczek-Fossa.  Postoperative irradiation in endometrial cancer: still a matter of controversy. , 2001, Cancer treatment reviews.

[12]  P. Koper,et al.  Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial , 2000, The Lancet.

[13]  J. Hall,et al.  The use of adjuvant radiation therapy by members of the Society of Gynecologic Oncologists. , 1999, Gynecologic oncology.

[14]  M. Chadha,et al.  Patterns of failure in endometrial carcinoma stage IB grade 3 and IC patients treated with postoperative vaginal vault brachytherapy. , 1999, Gynecologic oncology.

[15]  A. Fyles,et al.  The role of adjuvant radiotherapy in carcinoma of the endometrium-results in 550 patients with pathologic stage I disease. , 1998, Gynecologic oncology.

[16]  H. Yun,et al.  Long-term outcomes of therapeutic pelvic lymphadenectomy for stage I endometrial adenocarcinoma. , 1998, Gynecologic oncology.

[17]  B. Corn,et al.  Which prognostic factors influence the outcome of patients with surgically staged endometrial cancer treated with adjuvant radiation? , 1997, International journal of radiation oncology, biology, physics.

[18]  W. Eggleston,et al.  Prognostic characteristics of surgical stage I endometrial adenocarcinoma. , 1996, International journal of radiation oncology, biology, physics.

[19]  J. Fanning,et al.  Surgical Staging and High Dose Rate Brachytherapy for Endometrial Cancer: Limiting External Radiotherapy to Node‐Positive Tumors , 1996, Obstetrics and gynecology.

[20]  I. Strøyer,et al.  Adjuvant radiation therapy is not necessary in the management of endometrial carcinoma stage I, low‐risk cases , 1996 .

[21]  E. Partridge,et al.  Adenocarcinoma of the endometrium: survival comparisons of patients with and without pelvic node sampling. , 1995, Gynecologic oncology.

[22]  P. Grigsby,et al.  Clinical stage I endometrial cancer: prognostic factors for local control and distant metastasis and implications of the new FIGO surgical staging system. , 1992, International journal of radiation oncology, biology, physics.

[23]  R. Kurman,et al.  Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: A gynecologic oncology group study , 1991 .

[24]  W. Curran,et al.  Patterns of failure in patients with stage I, grade 3 carcinoma of the endometrium. , 1990, International journal of radiation oncology, biology, physics.

[25]  N. Vávra,et al.  Benefit of external irradiation in pathologic stage I endometrial carcinoma: a prospective clinical trial of 605 patients who received postoperative vaginal irradiation and additional pelvic irradiation in the presence of unfavorable prognostic factors. , 1990, Gynecologic oncology.

[26]  P. Koper,et al.  Endometrial adenocarcinoma, adjuvant radiotherapy tailored to prognostic factors. , 1990, International journal of radiation oncology, biology, physics.

[27]  R. Kurman,et al.  Doxorubicin as an adjuvant following surgery and radiation therapy in patients with high-risk endometrial carcinoma, stage I and occult stage II: a Gynecologic Oncology Group Study. , 1990, Gynecologic oncology.

[28]  B. Bundy,et al.  Surgical pathologic spread patterns of endometrial cancer: A gynecologic oncology group study , 1987, Cancer.

[29]  L. Brady,et al.  Failure patterns in gynecologic cancer. , 1986, International journal of radiation oncology, biology, physics.

[30]  V. Abeler,et al.  Postoperative External Irradiation and Prognostic Parameters in Stage I Endometrial Carcinoma: CLINICAL AND HISTOPATHOLOGIC STUDY OF 540 PATIENTS , 1980, Obstetrics and gynecology.